Furthermore, the flow chamber does not allow for pulsatile shear-flow conditions and realistic geometries similar to those encountered in small postcapillary venules, and most flow chamber assays do not include red blood cells.
Even though the primers used for this assay did not include CpG islands, a PCR bias (i.e. preferred amplification of unmethylated or methylated DNA), had to be excluded [ 30- 32].
The hpVIR assay does not include HPV 68.
Non-Mendelian transgene segregation has been noted in triticale [ 12], but since this observation was based on a histochemical reporter gene assay and did not include any DNA analysis, its basis could not be ascertained.
As the scope of this pilot project did not include functional validation assays, we refrain from speculating on the specific mechanisms by which individual genes may be involved in atherosclerosis development.
Of note, the PCR array did not include an assay for miR-371.
Another limitation was that we did not include an assay for testing anti-CCP3.
All pharmacokinetic studies in humans were reviewed, as abstracts often did not include normal microbiota assay data.
Our study did not include a quantitative assay for detection of virus in nasopharyngeal specimens; however, other studies have suggested that virus shedding may be less effectively reduced in recipients of TIV compared with recipients of LAIV [ 26– 28].
Furthermore, as the B14 and B20 studies did not include information about how a third assay, MammaPrint®, would classify patients into risk groups, this assay was not included in the current CEA.
In our review, we observed that 210 trials (90.5%) did not include a placebo arm to confirm assay sensitivity.
